Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8⁺ T cell responses

Graphical abstract

Highlights
- Anti-SARS-CoV-2 efficacy of an intranasal S-free vaccine is shown in macaques
- The SARS-CoV-2 control is associated with vaccine-induced CD8⁺ T cell responses
- Vaccine induction of CD8⁺ T cells can result in neutralization-free viral control
- Vaccine-induced CD8⁺ T cells may contribute to SARS-CoV-2 variant control

In brief
Ishii et al. show neutralization-independent SARS-CoV-2 control associated with vaccine-induced CD8⁺ T cell responses, indicating that virus-specific CD8⁺ T cell induction by intranasal vaccination can result in SARS-CoV-2 control. Results highlight the potential of vaccine-induced CD8⁺ T cell responses to contribute to the control of SARS-CoV-2 variants.

Authors
Hiroshi Ishii, Takushi Nomura, Hiroyuki Yamamoto, ..., Yuriko Suzaki, Yasushi Ami, Tetsuro Matano

Correspondence
tmatano@nih.go.jp

Ishii et al., 2022, Cell Reports Medicine 3, 100520

February 15, 2022 © 2022 The Author(s).
https://doi.org/10.1016/j.xcrm.2022.100520
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

Hiroshi Ishii,1,9 Takushi Nomura,1,9 Hiroyuki Yamamoto,1 Masako Nishizawa,1 Trang Thi Thu Hau,1 Shigeyoshi Harada,1 Sayuri Seki,1 Midori Nakamura-Hoshi,1 Midori Okazaki,1 Sachie Daigen,1 Ai Kawana-Tachikawa,1,2,3 Noriyu Nagata,4 Naoko Iwata-Yoshikawa,4 Nozomi Shiwa,1 Tadaki Suzuki,5 Eun-Sil Park,5 Maeda Ken,5 Taishi Onodera,6 Yoshimasa Takahashi,6 Kohji Kusano,7 Ryutarou Shimazaki,7 Yuriko Suzuki,8 Yasushi Ami,8 and Tetsuro Matano1,2,3,10,*

1AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
2Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan
3Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan
4Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
5Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
6Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
7ID Pharma Co., Ltd., Ibaraki 300-2611, Japan
8Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
9These authors contributed equally
10Lead contact
*Correspondence: tmatano@nih.go.jp
https://doi.org/10.1016/j.xcrm.2022.100520

SUMMARY

Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our results indicate that CD8+ T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T cell responses to contribute to COVID-19 containment.

INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread, resulting in a pandemic. SARS-CoV-2 transmission that can occur from asymptomatic infected individuals is difficult to control.1 Development of an effective vaccine is key for the control of the COVID-19 pandemic. Several effective vaccines using mRNAs or viral vectors have been rapidly developed and are currently in clinical use.2–5 Intramuscular administration of these vaccines elicits effective anti-SARS-CoV-2 neutralizing antibodies (NAbs), showing protective efficacy against COVID-19 onset and progression. Antibodies targeting the receptor-binding domain of the spike (S) antigen play a central role in virus neutralization.6,7

However, reports on SARS-CoV-2 variants have recently accumulated, and the appearance of NAb-resistant S variant viruses is of great concern.8–10 For example, B.1.351 (β variant), a variant of concern (VOC), has shown reduced sensitivity to neutralization not only by convalescent plasma of COVID-19 patients but also by plasma from vaccinated individuals.11–13 Hence, there is a demand for the development of a vaccine inducing effective immune responses against these NAb-resistant variants.14,15

While possible cross-reactivity of vaccine-induced NAb responses to variants has been indicated,16–19 induction of virus-specific T cell responses may be an alternative vaccine strategy to control VOC epidemics. Involvement of virus-specific T cell responses in the control of SARS-CoV-2 infection has been suggested.20,21 Early induction of functional virus-specific CD8+ T cell responses has been observed in convalescent COVID-19 individuals, implying contribution of CD8+ T cells in SARS-CoV-2 control.22 Whereas CD8+ depletion in rhesus macaques did not solely lead to viral control failure or severe disease
CD8+ depletion prior to SARS-CoV-2 re-infection in rhesus macaques resulted in partial abrogation of protection, suggesting the potential of CD8+ T cells to augment antibody-mediated viral control.23 Induction of SARS-CoV-2-specific T cell responses, including those reactive to VOCs, has been shown in several vaccines.2,24,36-39 while these vaccines were not S antigen free and also induced S-specific antibodies. Thus, T cell responses may play a role in vaccine efficacy, but the potential of vaccine-induced T cell responses to prevent SARS-CoV-2 infection in the absence of S-specific antibodies remains unclear.

In the present study, we investigated the protective efficacy of an intranasal S-free vaccine inducing T cell responses against SARS-CoV-2 challenge in cynomolgus macaques. Our results revealed significant association of viral suppression with vaccine-induced CD8+ T cell responses, indicating that CD8+ T cell induction by intranasal vaccination can result in S-independent or NAb-independent control of SARS-CoV-2 infection.

RESULTS

Induction of T cell responses targeting SARS-CoV-2 N, M, and E antigens by vaccination

We constructed plasmid DNAs expressing nucleocapsid (N), membrane (M), and envelope (E) antigens (pcDNA-N, pcDNA-M, and pcDNA-E, respectively) and a replication-incompetent F-deleted Sendai virus vector30 expressing N, M, and E (SeV-NME) for vaccination. We attempted two vaccine protocols in this study (Table S1). Three cynomolgus macaques (V11, V12, and V13) received intramuscular vaccination (prime) with pcDNA-N, pcDNA-M, and pcDNA-E twice on days 0 and 4 and intranasal vaccination (boost) with SeV-NME at week 5. The other four cynomolgus macaques (V14, V15, V16, and V17) received intranasal SeV-NME vaccination twice with a 5-week interval.

Vaccine-induced SARS-CoV-2 N-, M-, and E-specific T cell responses were measured by flow cytometric analysis of interferon-γ (IFN-γ) induction after specific stimulation using panels of overlapping peptides spanning the N, M, and E amino acid sequences, respectively (Figures S1A and S1B). We confirmed that these T cell responses were undetectable before vaccination in the vaccinated macaques (Figure S1C). These T cell responses were also undetectable before challenge in the unvaccinated macaques (Figure 2C). These T cell responses were also undetectable before challenge in the unvaccinated macaques (Figure S1D). The sum of N-specific, M-specific, and E-specific T cell frequencies is shown as NME-specific T cell responses (Figure 1). Analysis using peripheral blood mononuclear cells (PBMCs) 2 weeks after the last vaccination confirmed that NME-specific T cell responses were elicited in all seven immunized macaques, although efficiently in some animals, but not in others. In macaques V11, V12, and V13, NME-specific T cell responses were undetectable after the DNA prime (Figure S1E) but induced after the SeV-NME boost. It has been indicated that such heterologous prime-boost mostly can be more immunogenic than homologous prime-boost,31 and macaques V11 and V12 efficiently induced NME-specific CD4+ T cell and CD8+ T cell responses, whereas NME-specific CD4+ T cell responses were lower and CD8+ T cell responses were undetectable in macaque V13. In four macaques (V14, V15, V16, and V17) receiving SeV-NME twice, NME-specific CD4+ T cell and CD8+ T cell responses were detectable in three macaques except for V17, which showed only marginal NME-specific CD4+ T cell responses. SeV-specific CD4+ T cell and CD8+ T cell responses were efficiently induced in all of the vaccinated macaques (Figure S2A). By enzyme-linked immunosorbent assay (ELISA), anti-SARS-CoV-2 N antibodies were detected in post-vaccination plasma of all the vaccinated macaques (Figure S2B), whereas anti-M and anti-E antibodies were detectable only in macaque V16 (Figure S2C) and in macaques V16 and V17 (Figure S2D), respectively.

Reduction in viral loads in the vaccinated macaques compared with the unvaccinated controls after SARS-CoV-2 challenge

These vaccinated macaques were intranasally challenged with 105 50% tissue culture infective doses (TCID50) of SARS-CoV-2 wk521 (2019-nCoV/Japan/TY/WK-521/2020)32 at week 6 after the last vaccination. NME-specific CD4+ T cell and CD8+ T cell responses were detectable just before challenge in five and three macaques, respectively (Figure 1). None of these vaccinated macaques induced anti-SARS-CoV-2 NAb responses before SARS-CoV-2 challenge (Table S2). Four unvaccinated cynomolgus macaques (N031, N032, N041, and N042) were also intranasally challenged with 105 TCID50 of SARS-CoV-2. Data on additional five cynomolgus macaques intranasally infected with 106 TCID50 of the same SARS-CoV-2 stock in our previous study23 were used as historical unvaccinated controls (Table S1).

In the unvaccinated controls (n = 9), the geometric mean of viral RNA levels in nasopharyngeal swabs on day 2 post-challenge was 1.1 × 105 copies/swab (Figure 2A). One macaque N032 showed 5.6 × 105 copies/swab, but the remaining eight macaques had 6.9 × 103–1.1 × 106 copies/swab. In contrast, six of the seven vaccinated macaques showed less than 8.7 × 106 copies/swab of viral RNAs (Figure 2A). Comparison revealed significantly lower viral RNA levels in nasopharyngeal swabs on day 2 post-challenge in the vaccinated than the unvaccinated macaques (p = 0.0311 by Mann-Whitney U test; Figure 2B). Viral subgenomic RNAs (sgRNAs) in nasopharyngeal swabs were detected on day 2 post-challenge in eight of the nine unvaccinated controls but undetectable in six of the seven vaccinated macaques (Figure 2C), exhibiting significant reduction in the viral sgRNA levels in the vaccinated macaques compared with the unvaccinated controls (p = 0.0039 by Mann-Whitney U test; Figure 2D). Virus recovery from the nasopharyngeal swabs was consistent with viral RNA levels described above (Figure 2E), and a significant reduction in viral titers on day 2 post-challenge was observed in the vaccinated macaques compared with the unvaccinated (p = 0.0240 by Mann-Whitney U test; Figure 2F). These results indicate protective efficacy of the vaccination against intranasal SARS-CoV-2 challenge.

Correlation between viral control and vaccine-induced, NME-specific CD8+ T cell responses

We then investigated immune correlates for this protective efficacy in the seven vaccinated macaques. Remarkably, analysis
revealed a significant inverse correlation between viral RNA levels in nasopharyngeal swabs on day 2 post-challenge and NME-specific CD8⁺ T cell responses 2 weeks after the last vaccination (post-v) and just before SARS-CoV-2 challenge (pre-c; 6 weeks after the last vaccination). N-, M-, and E-specific T cell frequencies were calculated by subtracting nonspecific IFN-γ⁺ T cell frequencies from those after stimulation with overlapping peptides spanning the SARS-CoV-2 N, M, and E amino acid sequences, respectively. The sums of N-, M-, and E-specific CD4⁺ T cell and CD8⁺ T cell frequencies above the cutoff value (0.02%) are shown as NME-specific CD4⁺ T cell (open box) and CD8⁺ T cell (closed box) responses, respectively. Macaques V11, V12, and V13 shown in upper panels received pcDNA-N/M/E prime followed by SeV-NME boost. Macaques V14, V15, V16, and V17 shown in lower panels received SeV-NME vaccination twice. See also Figure S1.

Figure 1. SARS-CoV-2 NME-specific T cell responses after vaccination
SARS-CoV-2 N-, M-, and E-antigen-specific CD4⁺ T cell and CD8⁺ T cell responses were examined using PBMCs obtained 2 weeks after the last vaccination (post-v) and just before SARS-CoV-2 challenge (pre-c; 6 weeks after the last vaccination). N-, M-, and E-specific T cell frequencies were calculated by subtracting nonspecific IFN-γ⁺ T cell frequencies from those after stimulation with overlapping peptides spanning the SARS-CoV-2 N, M, and E amino acid sequences, respectively. The sums of N-, M-, and E-specific CD4⁺ T cell and CD8⁺ T cell frequencies above the cutoff value (0.02%) are shown as NME-specific CD4⁺ T cell (open box) and CD8⁺ T cell (closed box) responses, respectively. Macaques V11, V12, and V13 shown in upper panels received pcDNA-N/M/E prime followed by SeV-NME boost. Macaques V14, V15, V16, and V17 shown in lower panels received SeV-NME vaccination twice. See also Figure S1.

by Spearman’s test; Figure S3A). We confirmed no significant correlation between the viral RNA levels and vaccine-induced, SeV-specific CD4⁺ T cell or CD8⁺ T cell responses (Figure S3B). No significant correlation was observed between viral RNA levels in nasopharyngeal swabs on day 2 post-challenge and vaccine-induced anti-N antibody levels (Figure S3C), although significant correlation between the anti-N antibody levels and vaccine-induced N-antigen-specific CD8⁺ T cell responses was indicated (Figure S3D). Anti-M and anti-E antibodies post-vaccination were detectable in only one or two vaccinated macaques but undetectable in macaques V11 and V12 that showed the top two
Figure 2. Viral loads in nasopharyngeal swabs after intranasal SARS-CoV-2 challenge

(A) Changes in viral RNA levels in nasopharyngeal swabs after SARS-CoV-2 challenge in the nine unvaccinated controls (U; black; left panel) and the seven vaccinated macaques (V; red; right panel). Data on three macaques (V11, V12, and V13) vaccinated with pcDNA-N/M/E prime/SeV-NME boost are indicated by open symbols. Data on day 0 are those just before challenge. Viral RNA levels less than $3 \times 10^3$ copies/swab were undetectable.

(B) Comparison of viral RNA levels on day 2 post-challenge between unvaccinated (U) and vaccinated (V) macaques. Vaccinated macaques showed significantly lower viral RNA levels compared with the unvaccinated controls (by Mann-Whitney U test).

(C) Changes in viral sgRNA levels in nasopharyngeal swabs in U and V. Viral sgRNA levels less than $3 \times 10^3$ copies/swab were undetectable.

(D) Comparison of viral sgRNA levels on day 2 post-challenge between unvaccinated (U) and vaccinated (V) macaques. Vaccinated macaques showed significantly lower viral sgRNA levels compared with the unvaccinated controls (by Mann-Whitney U test).

(E) Changes in viral titers in nasopharyngeal swabs in U and V. Swab samples with virus titers greater than $1 \times 10^5$ TCID$_{50}$/swab were considered positive.

(F) Comparison of viral titers on day 2 between U and V. Vaccinated macaques showed significantly lower viral titers compared with the unvaccinated controls (by Mann-Whitney U test). Data on historical unvaccinated controls N012, N013, N022, D024, and D025 were described before.
lowest viral RNA levels in nasopharyngeal swabs on day 2 post-challenge (Figures S2C and S2D). Significant inverse correlation was observed between NME-specific CD8+ T cell responses 2 weeks after the last vaccination and viral RNA levels in nasopharyngeal swabs on day 5 (p = 0.0044; \( r = 0.9455 \) by Spearman’s test), but not on day 7 (p = 0.0508; \( r = 0.7748 \) by Spearman’s test) post-challenge (Figures S3E and S3F).

Viral titers in nasopharyngeal swabs on day 2 post-challenge were also inversely correlated with the vaccine-induced, NME-specific CD8+ T cell responses (p = 0.0071; \( r = 0.9346 \) by Spearman’s test; Figure 3B). The three vaccinated macaques (V11, V12, and V16) that exhibited the top three highest frequencies of vaccine-induced, NME-specific CD8+ T cells showed no virus recovery post-challenge (Figure 2E).

Analysis of tissues obtained at necropsy on day 7 or 9 post-challenge detected viral sgRNA in the pharyngeal mucosa and/or retropharyngeal lymph nodes (RPLNs) of the four unvaccinated controls (Table S3). It should be noted that sgRNA in the pharyngeal mucosa was detected even in macaque N032, despite low viral RNA levels in nasopharyngeal swabs. In contrast, viral sgRNA was undetectable in the pharyngeal mucosa and RPLNs in the three vaccinated macaques (V11, V12, and V16) that exhibited the top three highest frequencies of vaccine-induced, NME-specific CD8+ T cells. Viral RNA levels in nasopharyngeal swabs on day 7 post-challenge were greater than \( 10^5 \) copies/swab in all of the unvaccinated macaques but less than \( 10^4 \) copies/swab in these three vaccinated macaques (Figure 2A). Thus, in these three, sgRNA was undetectable not only in nasopharyngeal swabs but also in the pharyngeal mucosa and RPLNs obtained at necropsy (Table S3).

Analysis using PBMCs on day 7 post-challenge detected NME-specific CD8+ T cell responses in five of the seven vaccinated macaques (Figure 4A). In contrast, analysis using lymphocytes derived from the submandibular lymph nodes (SMLNs) obtained at necropsy on day 7 or 9 post-challenge detected NME-specific CD8+ T cell responses in all of the seven vaccinated macaques (Figure 4B). The NME-specific CD8+ T cell frequencies in SMLNs in the vaccinated were significantly higher than the four unvaccinated macaques (N031, N032, N041, and N042; p = 0.0394 by Mann-Whitney U test). NME-specific CD8+ T cell responses in the lung were detected in six vaccinated macaques except for V13, showing the highest viral RNA level in the nasopharyngeal swab on day 2 (Figure 4C).

**DISCUSSION**

This study is the first to show a significant association between SARS-CoV-2 control and vaccine-induced T cell responses in the absence of NAbs, indicating that induction of SARS-CoV-2-specific CD8+ T cell responses by intranasal vaccination can contribute to the control of SARS-CoV-2 infection. We recognize that induction of T cell responses by our vaccine is not consistently efficient and two vaccine protocols were attempted in the present study, but thereby, the vaccination resulted in various levels of T cell responses and viral protection, which enabled us to determine the important immune correlates. Further optimization of an intranasal vaccine protocol using more immunogenic delivery systems would lead to efficient and durable SARS-CoV-2-specific CD8+ T cell induction, possibly resulting in enhanced protection, which could bring SARS-CoV-2...
variants under control. Furthermore, our results might support a notion that CD8\(^+\) T cell responses induced by currently developed S-expressing vaccines may contribute to variant control.

The present study showed significant inverse correlation of viral RNA levels in nasopharyngeal swabs on day 2 post-challenge with vaccine-induced, NME-specific CD8\(^+\) T cell, but not CD4\(^+\) T cell responses, indicating the association of viral control with vaccine-induced, NME-specific CD8\(^+\) T cell responses (Figure 3). Viral control was not associated with vaccine-induced antibodies nor SeV-specific T cell responses, which might reflect vaccine-induced nonspecific immune responses (Figures S3B and S3C). Significant inverse correlation was observed between
vaccine-induced, NME-specific CD8+ T cell responses and viral RNA levels in nasopharyngeal swabs on day 5 (p = 0.0044 in Figure S3E), but not on day 7 (p = 0.0508; Figure S3F). It may reflect the following two points. First, the three vaccinated macaques (V11, V12, and V16) that exhibited the top three highest vaccine-induced CD8+ T cell responses on viral control. Second, in the other four macaques with inefficient vaccine-induced CD8+ T cell responses and inefficient suppression of viral replication post-challenge, viral replication 1 week post-infection could be affected also by vaccine-independent immune responses induced post-infection.

Vaccine-induced, NME-specific CD8+ T cell responses detected in PBMCs may not directly work for the rapid viral control after the intranasal SARS-CoV-2 challenge. However, our finding of the immuno-correlate might imply direct contribution of vaccine-induced mucosal CD8+ T cell responses around the pharyngeal mucosa to rapid viral control. It is speculated that vaccine-induced peripheral NME-specific CD8+ T cell responses around the peak (rather than just before challenge) are indicative of efficient mucosal NME-specific CD8+ T cell responses around the pharyngeal mucosa. Indeed, our previous study showed the potential of intranasal immunization with a SeV vector expressing simian immunodeficiency virus Gag to induce Gag-specific T cell responses in the tonsil, nasal mucosa, and its primary lymph nodes (RPLN and SMLN)..

In our cynomolgus model of SARS-CoV-2 infection, kinetics of viral sgRNA levels in nasopharyngeal swabs (geometric mean on day 2: 4.3 x 10^5 copies/swab) in unvaccinated controls were similar to those for evaluation of NAb-inducing vaccine efficacy in other groups. Thus, our results of undetectable viral sgRNAs in nasopharyngeal swabs from six of the seven vaccinated macaques suggest that the reduction in nasopharyngeal viral load by efficient NME-specific CD8+ T cell responses is comparable with that by effective NAb-inducing vaccines.

In addition to the data on viral load in nasopharyngeal swabs, we had data on viral sgRNA in the pharyngeal mucosa, RPLN, and the lung obtained at necropsy (Table S3). Viral sgRNA in the lung was undetectable in all the unvaccinated and vaccinated macaques, while bronchoalveolar lavage (BAL) was unexamined. Viral sgRNA in RPLN was detectable in three of the four unvaccinated macaques but undetectable in all the seven vaccinated. Viral sgRNA in the pharyngeal mucosa was detected in the four vaccinated macaques (V13, V14, V15, and V17) with inefficient vaccine-induced, NME-specific CD8+ T cell responses but undetectable in the three vaccinated macaques (V11, V12, and V16) that exhibited the top three highest frequencies of vaccine-induced, NME-specific CD8+ T cells, supporting our conclusion of association of viral control with vaccine-induced CD8+ T cell responses. These three vaccinated macaques with efficient vaccine-induced, NME-specific CD8+ T cell responses controlled SARS-CoV-2 replication without detectable virus recovery from nasopharyngeal swabs or sgRNAs in the pharyngeal mucosa. Although complete protection may be difficult, the rapid reduction in nasopharyngeal viral load that was shown in the present study would be important for inhibition of SARS-CoV-2 transmission from vaccinated but infected individuals, which could be a key for the control of COVID-19 pandemic.

Viral sgRNAs were undetectable in the lung for all animals, regardless of vaccination status, as described above (Table S3). However, histopathological analysis of the lung obtained at necropsy on days 7 or 9 post-challenge confirmed lesions in multiple lobes in all of the seven vaccinated and the four unvaccinated macaques (Figure S4). Epithelial degeneration and/or infiltration of macrophages, neutrophils, eosinophils, or mononuclear cells were detected, whereas no severe bronchiolitis or intestinal pulmonary inflammation was observed. It is speculated that even the vaccinated macaques efficiently inducing NME-specific CD8+ T cell responses allowed SARS-CoV-2 infection in the lung but rapidly exerted immune responses, resulting in prompt control of viral replication. However, we should be careful about a possibility that virus-specific T cell induction by vaccination can result in aberrant pulmonary inflammation post-virus exposure, which could be a next subject to be addressed.

In summary, this pre-clinical study presents evidence indicating that induction of SARS-CoV-2-specific CD8+ T cell responses by intranasal vaccination can result in the control of SARS-CoV-2 infection in the absence of NAb. A rapid reduction in nasopharyngeal viral load could greatly contribute to the control of SARS-CoV-2 transmission. Although careful assessment of possible vaccine effect on pulmonary inflammation may be required, the present study highlights the potential of vaccine-induced T cell responses to contribute to the control of SARS-CoV-2 variants, providing a rationale of facilitating studies on vaccines inducing T cells in addition to NAb for COVID-19 containment.

**Limitations of the study**

This study showed a significant association between SARS-CoV-2 control and vaccine-induced CD8+ T cell responses. However, the vaccine-induced, NME-specific CD8+ T cell responses detected in PBMCs may not directly work for the rapid viral control after the intranasal SARS-CoV-2 challenge. Contribution of vaccine-induced mucosal CD8+ T cell responses around the pharyngeal mucosa to rapid viral control is speculated, but we had no data on mucosal CD8+ T cell responses just before challenge in the present study. It is difficult to obtain sufficient lymphocytes around the pharyngeal mucosa by biopsy just before challenge for T cell analysis. Analysis of samples obtained from the pharyngeal mucosa by necropsy before challenge and/or BAL-derived lymphocytes that may be useful to investigate T cell responses in the lung could be the next issue.

**STAR★METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
AUTHOR CONTRIBUTIONS

H.I., T.N., and T.M. conceived and designed the experiments. K.K. and R.S. produced SeV vectors. H.I., T.N., H.Y., M.N., T.T.T.H., S.H., S.S., M.O., T.M.-H., N.N., N.I.-Y., N.S., T.S., Y.S., and Y.A. performed macaque experiments. H.I., T.N., T.M., N.I., T.S., Y.T., and Y.T. performed virological and immunological analyses. N.N., N.I.-Y., N.S., and T.S. performed pathological analyses. H.I., T.N., and T.M. analyzed the data. H.I., T.N., and T.M. wrote the paper.

DECLARATION OF INTERESTS

H.I., K.K., R.S., and T.M. are inventors on Patent Cooperation Treaty (PCT) application for SeV-NME vaccine. The authors declare no other competing interests.

Received: September 8, 2021
Revised: November 27, 2021
Accepted: January 13, 2022
Published: January 19, 2022

REFERENCES

1. Moghadas, S.M., Fitzpatrick, M.C., Sah, P., Pandey, A., Shoukat, A., Singer, B.H., and Galvani, A.P. (2020). The implications of silent transmission for the control of COVID-19 outbreaks. Proc. Natl. Acad. Sci. U S A 117, 17315–17315.

2. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2003–2015.

3. Baden, L.R., El Sahly, H.M., Essink, B., Koff, K., Frey, S., Novak, R., D'Emert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416.

4. Voysey, M., Clemens, S., Madh, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Bailie, V.L., Barnabas, S.L., Bhorat, O.E., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111.

5. Sadow, J., Gray, G., Vandenbosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truayers, C., Fennema, H., Spiessens, B., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N. Engl. J. Med. 384, 2187–2201.

6. Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.A., Esswein, S.R., Gristick, H.B., Malyutin, A.G., Sharaf, N.A., Huey-Tubman, K.E., Lee, Y.E., et al. (2020). SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687.

7. Yuan, M., Liu, H., Wu, N.C., and Wilson, I.A. (2021). Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem. Biophys. Res. Commun. 538, 192–203.

8. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Guarini, H., Doolabh, D., Pillay, S., San, E.J., Maomi, N., et al. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443.

9. Washington, N.L., Gangavarapu, K., Zeller, M., Bolze, A., Cirilli, E.T., Schiabor Barrett, K.M., Larsen, B.B., Anderson, C., White, S., Cassens, T., et al. (2021). Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184, 2587–2594.e7.

10. Boehm, E., Kronig, I., Neher, R.A., Eckerle, I., Vetter, P., and Kaiser, L.: Geneva Centre for Emerging Viral Diseases (2021). Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin. Microbiol. Infect. 27, 1109–1117.

11. Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Gin, H.M., Zhao, Y., Duyvesteyn, H., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from neutral and vaccine-induced sera. Cell 184, 2348–2361.e6.

12. Hoffmann, M., Arora, P., Groth, R., Seidel, A., Hörmann, B.F., Hahn, A.S., Krüger, N., Graichen, L., Hoffmann-Winkler, H., Kempf, A., et al. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e12.

13. Wang, P., Nair, M.S., Liu, L., Ikotani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D., et al. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135.

14. Krause, P.R., Fleming, T.R., Longini, I.M., Peto, R., Briand, S., Heymann, D.L., Beral, V., Snape, M.D., Rees, H., Popper, A.M., et al. (2021). SARS-CoV-2 variants and vaccines. N. Engl. J. Med. 385, 179–186.

15. Tregoning, J.S., Flight, K.E., Higham, S.L., Wang, Z., and Pierce, B.F. (2021). Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636.

16. Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021). Evidence of escape of SARS-CoV-2 variants B.1.617.2 (Delta) variant versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636.

17. Pegu, A., O’Connell, S., Schmidt, S.D., O’Dei, S., Talana, C.A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K.S., et al. (2021). Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 373, 1372–1377.

18. Urbanowicz, R.A., Tsoleirdis, T., Jackson, H.J., Cusin, L., Duncan, J.D., Chappell, J.G., Tarr, A.W., Nightingale, J., Norrish, A.R., Ikrar, A., et al. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci. Transl. Med. 13, eaab6847.

19. Yu, J., Tostanoski, L.H., Mercado, N.B., McMahen, K., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Atyeo, C., Martinez, D.R., Anoke, T., et al.
(2021). Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature 596, 423–427.

20. Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020). Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345.

21. Rydzynski Moderbacher, C., Ramirez, S.L., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D., Belanger, S., Abbott, R.K., Kim, C., Choi, J., et al. (2020). Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996–1012.e19.

22. Tan, A.T., Linster, M., Tan, C.W., Le Bert, N., Chia, W.N., Kunasegaran, K., Zhuang, Y., Tham, C., Chia, A., Smith, G., et al. (2021). Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728.

23. Nomura, T., Yamamoto, H., Nishizawa, M., Hau, T., Harada, S., Ishii, H., Seki, S., Nakamura-Hoshi, M., Okazaki, M., Daigen, S., et al. (2021). Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. PLoS Pathog. 17, e1009668.

24. Hasenkrug, K.J., Feldmann, F., Myers, L., Santiago, M.L., Guo, K., Barrett, B.S., Mickens, K.L., Carmody, A., Okumura, A., Yao, S., et al. (2021). Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques. mBio 12, e0150321.

25. McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634.

26. Mercado, N.B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L.H., et al. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588.

27. Routhu, N.K., Cheedarla, N., Gangadhara, S., Bollimpelli, V.S., Boddapati, A.K., Shiferaw, A., Rahman, S.A., Sahoo, A., Edara, V.V., Lai, L., et al. (2021). A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity 54, 542–556.e9.

28. Atter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan, K., Jacob-Dolan, C., Martinez, D.R., Chang, A., et al. (2021). Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 596, 268–272.

29. Painter, M.M., Mathew, D., Goel, R.R., Apostolidis, S.A., Pattekar, A., Kuthuru, O., Baxter, A.E., Herati, R.S., Oldridge, D.A., Gourna, S., et al. (2021). Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133–2142.e3.

30. Matano, T., Kobayashi, M., Igarashi, H., Takeda, A., Nakamura, H., Kano, M., Sugimoto, C., Mori, K., Iida, A., Hirata, T., et al. (2004). Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199, 1709–1718.

31. Lu, S. (2009). Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346–351.

32. Matsuyama, S., Sano, K., Takayama, K., Kawase, T., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020). Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U S A. 117, 7001–7003.

33. Takeda, A., Igarashi, H., Nakamura, H., Kano, M., Iida, A., Hirata, T., Hasegawa, M., Nagai, Y., and Matano, T. (2003). Protective efficacy of an AIDS vaccine, a single DNA-prime followed by a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Virol. 77, 9710–9715.

34. Takeda, A., Igarashi, H., Kawada, M., Tsukamoto, T., Yamamoto, H., Inoue, M., Iida, A., Shu, T., Hasegawa, M., and Matano, T. (2008). Evaluation of the immunogenicity of replication-competent V-knockouted and replication-defective F-deleted Sendai virus vector-based vaccines in macaques. Vaccine 26, 6839–6843.

35. Li, H.O., Zhu, Y.F., Asakawa, M., Kuma, H., Hirata, T., Ueda, Y., Lee, Y.S., Fukumura, M., Iida, A., Kato, A., et al. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74, 6564–6569.

36. Ishii, H., Terahara, K., Nomura, T., Takeda, A., Okazaki, M., Yamamoto, H., Tokusumi, T., Shu, T., and Matano, T. (2020). A novel immunogen selectively eliciting CD8+ T cells but not CD4+ T cells targeting immunodeficiency virus antigens. J. Virol. 94, e01876–19.

37. Shirato, K., Nao, N., Katano, H., Takayama, I., Saito, S., Katoh, H., Sakata, M., Nakatsu, Y., Mori, Y., et al. (2020). Development of genetic diagnostic methods for detection of novel coronavirus 2019-nCoV-2019 in Japan. Jpn. J. Infect. Dis. 73, 304–307.

38. Nagata, N., Iwata-Yoshikawa, N., Sano, K., Aina, S., Shiu, N., Shirakura, M., Kishida, N., Arita, T., Suzuki, Y., Harada, T., et al. (2021). The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.01.07.425698v1.

39. Moriyama, S., Adachi, Y., Sato, T., Tonouchi, K., Sun, L., Fukushima, S., Yamada, S., Kinoshita, H., Nojima, K., Kanno, T., et al. (2021). Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54, 1841–1852.e4.
**STAR METHODS**

**KEY RESOURCES TABLE**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Human CD4 (clone M-T477) FITC | BD | Cat# 556615; RRID: AB_396487 |
| Human CD8 (clone SK1) PerCP | BD | Cat# 347314; RRID: AB_400280 |
| Human CD3 (clone SP34-2) APC-Cy7 | BD | Cat# 557757; RRID: AB_396863 |
| Human IFN-g (clone 4S.B3) PE | Biolegend | Cat# 502510; RRID: AB_315235 |
| LIVE/DEAD Fixable Aqua Dead Cell Stain Kit | Invitrogen | Cat# L34957 |
| HRP-conjugated anti-monkey IgG | Bethyl Laboratories | Cat# A140-102P; RRID: AB_67118 |
| **Bacterial and virus strains** |        |            |
| SARS-CoV-2 (strain wk-521) | Matsuyama et al., 2020 | GenBank Accession # LC522975 |
| F-deleted Sendai virus expressing N, M, and E (SeV-NME) | This manuscript | N/A |
| **Biological samples** |        |            |
| Blood, swab, and tissue samples from cynomolgus macaques | This manuscript | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Dulbecco’s modified Eagle’s medium (DMEM) | GIBCO | Cat# 11965-118 |
| Phosphate Buffered Salts (PBS) | GIBCO | Cat# 10010-049 |
| Penicillin/Streptomycin | GIBCO | Cat# 15140122 |
| Fetal bovine serum | Cytiva | Cat# SH30396.03 |
| Ficoll-Paque PLUS | Cytiva | Cat# 17144002 |
| GolgiStop (monensin) | BD | Cat# 554724 |
| Tween-20 | SIGMA | Cat# P1379 |
| Bovine serum albumin (BSA) | SIGMA | Cat# A8412 |
| TMB substrate solution | Thermo Fisher Scientific | Cat# 34028 |
| Overlapping peptides spanning the SARS-CoV-2 N | JPT Peptide Technologies | Cat# PM-WCPV-NCAP-1 |
| Overlapping peptides spanning the SARS-CoV-2 M | Thermo Fisher Scientific | Cat# PM-WCPV-VME-1 |
| Overlapping peptides spanning the SARS-CoV-2 E | Thermo Fisher Scientific | Cat# PM-WCPV-VEMP-1 |
| recombinant SARS-CoV-2 M protein | RayBiotech | Cat# 230-01124 |
| recombinant SARS-CoV-2 E protein | AcroBiosystems | Cat# ENN-C5128 |
| **Critical commercial assays** |        |            |
| QIAamp Viral RNA Minikit | QIAGEN | Cat# 52906 |
| QuantiTect Probe RT-PCR Kit | QIAGEN | Cat# 204443 |
| Cytofix/Cytoperm kit | BD | Cat# 554714 |
| TRizol Plus RNA Purification Kit | Thermo Fisher Scientific | Cat# 12183555 |
| Exp293 expression system | Thermo Fisher Scientific | Cat# A29133 |
| TALON resin affinity chromatography | Clontech | Cat# 635503 |
| **Experimental models: Cell lines** |        |            |
| African green monkey (Chlorocebus sabaeus): Vero, VeroE6/TMPRSS2 cells | Matsuyama et al., 2020 | N/A |
| Autologous herpesvirus papio-immortalized B-lymphoblastoid cell lines (B-LCLs) | This manuscript | N/A |
| Exp293F | Thermo Fisher Scientific | Cat# A14527 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Requests for additional information and resources should be directed to the lead contact, Tetsuro Matano (tmatano@nih.go.jp).

Materials availability
All resources generated in this study are available from the lead contact upon request with a completed Materials Transfer Agreement.

Data and code availability
All data supporting the conclusion in this study are included in the main text and figures with supplemental information, and additional information will be available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals
Animal experiments using cynomolgus macaques (Macaca fascicularis, 3-7 years old) were performed at the National Institute of Infectious Diseases (NIID) after approval by the Committee on the Ethics of Animal Experiments in NIID (permission number: 520001) under the guidelines for animal experiments in accordance with the Guidelines for Proper Conduct of Animal Experiments established by the Science Council of Japan (http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf). Gender and age of animals used in this study are described in Table S1. Blood and nasopharyngeal swab collection, vaccination, and virus inoculation were performed under ketamine anesthesia. Macaques were euthanized by whole blood collection under deep anesthesia and subjected to necropsy on day 7 or 9 post-infection.

Cell lines
Vero and VeroE6/TMPRSS2 cells (Matsuyama et al., 2020) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO) supplemented with 10% heat-inactivated fetal bovine serum (Cytiva) and 50 U/mL penicillin/streptomycin (Thermo Fisher Scientific) at 37°C supplied with 5% CO2. Expi293F cells (Thermo Fisher Scientific) were maintained in Expi293 expression medium (Thermo Fisher Scientific).
Animal experiments
For vaccination, we constructed pcDNA-N, pcDNA-M, and pcDNA-E plasmid DNAs by introducing cDNAs encoding nucleocapsid (N), membrane (M), and envelope (E) proteins of the SARS-CoV-2 wk-521 strain (2019-nCoV/Japan/TY/WK-521/2020, GenBank Accession LC522975), respectively, into pcDNA3.1 (Invitrogen). We also constructed a replication-incompetent F-deleted Sendai virus (SeV) vector expressing N, M, and E (SeV-NME). We used two vaccine protocols in this study (Table S1). The first group of three cynomolgus macaques (V11, V12, and V13) received intramuscular vaccination with pcDNA-N (4 mg), pcDNA-M (2 mg), and pcDNA-E (2 mg) twice on days 0 and 4 and intranasal vaccination with SeV-NME (5 × 10⁸ cell infectious unit [CIU]) at week 5 after the first vaccination. The second group of four cynomolgus macaques (V14, V15, V16, and V17) received intranasal SeV-NME vaccination twice with a 5-week interval.

SARS-CoV-2 wk-521 was expanded in Vero E6/TMPRSS2 cells and harvested to prepare a virus challenge stock. Virus infectivity was assessed by detection of cytopathic effect (CPE) on Vero E6/TMPRSS2 cells and determination of endpoint titers. Virus challenge experiments 1 and 2 were performed separately because of the limitation of cage numbers in the facility. All of the challenge experiments were performed using the same SARS-CoV-2 stock. Vaccinated cynomolgus macaques were intranasally challenged with 10⁸ (exactly 7.5 × 10⁷) TCID₅₀ of SARS-CoV-2 at week 6 after the last vaccination. Four unvaccinated cynomolgus macaques (N031, N032, N041, and N042) were also intranasally challenged with 10⁵ TCID₅₀ of SARS-CoV-2. Macaques were euthanized and subjected to necropsy on day 7 (V12, V14, V15, N032, and N041) or 9 (V11, V13, V16, N031, and N042) post-infection. Data on additional five cynomolgus macaques (N012, N013, N022, D024, and D025) intranasally infected with 10⁵ TCID₅₀ of the same SARS-CoV-2 stock in our previous study were used as historical unvaccinated controls (Table S1).

Analysis of antigen-specific T-cell responses
Viral antigen-specific T-cell frequencies were measured by flow cytometric analysis of interferon-γ (IFN-γ) induction after specific stimulation as described previously. PBMCs were prepared from whole blood by density gradient centrifugation using Ficoll-Paque PLUS (Cytiva). Lymph node-derived lymphocytes were prepared from minced lymph nodes by density gradient centrifugation using Ficoll-Paque PLUS. For analysis of SARS-CoV-2 N-, M-, and E-specific T-cell responses, autologous herpervirus papio-immortalized B-lymphoblastoid cell lines (B-LCLs) were pulsed with peptide pools (at a final concentration of more than 0.1 μg/ml) from overlapping peptides spanning the SARS-CoV-2 N, M, and E amino acid sequences (PM-WCPV-NCAP-1, PM-WCPV-VME-1, and PM-WCPV-VEMP-1; JPT Peptide Technologies). For analysis of SeV-specific T-cell responses, autologous B-LCLs were infected with SeV. PBMCs or lymph node-derived lymphocytes were cocultured with these B-LCLs in the presence of GolgiStop (monensin, BD) and PM-WCPV-VEMP-1; JPT Peptide Technologies). For analysis of SeV-specific T-cell responses, autologous B-LCLs were infected with SeV. PBMCs or lymph node-derived lymphocytes were cocultured with these B-LCLs in the presence of GolgiStop (monensin, BD) for 6 hours. Intracellular IFN-γ staining was performed using a Cytofix/Cytoperm kit (BD) with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen), anti-CD3 APC-Cy7 (SP34-2; BD), anti-CD4 FITC (M-T477; BD), anti-CD8 PerCP (SK1; BD), and anti-IFN-γ PE (4S.B3; BioLegend). Stained cells were analyzed by BD FACs Canto II with FACS Diva v8.0.1 (BD) and FlowJo v9.2 (FlowJo LLC). Specific T-cell frequencies were calculated by subtracting nonspecific IFN-γ+ T-cell frequencies from those after peptide-specific stimulation. Specific T-cell frequencies more than 0.02% of CD4+ or CD8+ T cells were considered positive.

Detection of SARS-CoV-2 RNAs
Swab RNAs were extracted from 0.2 ml of swab solutions (1 ml of DMEM with 2% fetal bovine serum [Cytiva]) using QiAamp Viral RNA Minikit (QIAGEN) and subjected to real-time RT-PCR for viral RNA quantitation using QuantStudio 5 (Thermo Fisher Scientific). Swab RNAs were also subjected to real-time RT-PCR for measurement of viral subgenomic RNA (sgRNA) levels using the following primers: SARS2-LeaderF60 (5'-CGATCTCTTTAGATCTGGTC-3'), SARS2-N28354R (5'-TCTGAGGGTCCACCAAACGT-3'), and SARS2-N28313Fam (FAM-TCAGCGAAATGCACCCCGCA-TAMRA). Viral RNA or sgRNA levels less than 3 copies/swab were undetectable. Tissue RNAs were extracted from homogenized tissues by using TRIzol Plus RNA Purification Kit (Thermo Fisher Scientific) with phenol-chloroform extraction and subjected to real-time RT-PCR for detection of viral RNAs.

Virus recovery from swabs
Vero E6/TMPRSS2 cells in 96-well plates were added with 10-fold serially diluted swab solutions and cultured for 4 days without medium change. Virus recovery was assessed by detection of CPE and determination of endpoint titers. Swab samples with virus titers greater than 1 × 10⁵ TCID₅₀/swab were considered positive.

Analysis of SARS-CoV-2-specific NAb responses
Endpoint plasma titers for inhibiting 20 TCID₅₀ of SARS-CoV-2 infection on Vero cells were measured as described previously. Plasma samples were heat inactivated for 30 min at 56°C. Serial two-fold dilutions of heat-inactivated plasma were tested in quadruplicate. In each mixture for quadruplicate testing, 40 μl of diluted plasma were incubated with 40 μl of 80 TCID₅₀ SARS-CoV-2 wk-521. After incubation for 45 min at room temperature, 20 μl of the mixture was added to each of four wells (1 × 10⁵ Vero cells/well) in a 96-well plate. Three days later, virus infectivity was assessed by detection of CPE to determine the endpoint titers. The lower limit of detection was 1:10.
Analysis of SARS-CoV-2 N-, M-, and E-specific binding antibody responses

For preparation of a recombinant N antigen, the synthesized human codon-optimized nucleotide sequence encoding the N protein of the SARS-CoV-2 (GenBank Accession MN994467) was obtained from Eurofins Genomics. The cDNA encoding N protein (amino acids 1-419) along with the signal peptide (amino acids 1-24; MPMGSLQPLATLYLLGMLVASCLG), a histidine-tag (HHHHHHHHHH), and an avi-tag (GLNDIFEAQKIEWHE) was cloned into a CMV promoter-driven expression plasmid, and the plasmid was transfected into Expi293F cells (Thermo Fisher Scientific). The culture supernatant was harvested on day 5 post-transfection and subjected to purification of the recombinant N protein using a TALON resin affinity chromatography (Clontech). SARS-CoV-2 N-, M-, and E-specific binding antibody responses in plasma were measured by ELISA using the recombinant N protein described above, a recombinant SARS-CoV-2 M protein (RayBiotech), and a recombinant SARS-CoV-2 E protein (AcroBiosystems). The 96-well high-binding, half-area plates (Corning) were coated with the recombinant proteins (N: 1 µg/ml; M: 1 µg/ml; E: 0.2 µg/ml) at 4°C overnight. The plates were washed in PBS containing 0.05% Tween-20 and blocked with PBS containing 3% bovine serum albumin (BSA; Sigma) at 37°C for 1 hour. The antigen-coated plates were incubated with plasma diluted by 100 for N, 500 for M, and 1,000 for E, respectively, at 37°C for 1 hour. Antibodies bound to antigens were detected by OD_{450} after treatment with horseradish peroxidase (HRP)-conjugated anti-monkey IgG (Bethyl Laboratories) followed by TMB substrate solution (Thermo Fisher Scientific). A cut-off value was determined by the “Mean + 3 × SD” value, where Mean is the mean and SD is the standard deviation of negative control (without plasma) samples.

Histopathological analysis of the lung tissue obtained at necropsy

Hematoxylin and eosin (H&E)-stained samples were obtained from individual lobes (right upper, middle, lower, and accessory lobes and left upper [upper-middle], middle, and lower lobes). The number of lobes exhibiting lesions (epithelial degeneration with cell debris, slight peri-bronchial inflammatory cell infiltration, macrophage accumulation with alveolar wall thickening, interstitial infiltration of neutrophils, eosinophils, or mononuclear cells with airspace macrophages, and/or lymphoid cell aggregation in bronchial associated lymphoid tissue [BALT] or around blood vessels) was counted (Figure S4). No severe bronchiolitis or intestinal pulmonary inflammation was observed.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses were performed using Prism software (GraphPad Software, Inc.) with significance set at p values of <0.05. Comparisons were performed by Mann-Whitney U test. Correlation analyses were performed by Spearman’s test.